ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded a delivery order under the base contract SPE2DP-20-D-0002 to TEVA PHARMACEUTICALS USA, INC. (CAGE 3V8D7) for the supply of 54 units of ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV (NDC 51285-0138-50) at a total contract price of $1,030,579.20, with an award date of July 14, 2026. The order requires full delivery to be completed by July 21, 2026, under FOB destination terms, with inspection and acceptance occurring at the destination point. The vaccine is to be shipped via the fastest traceable means, excluding parcel post, to the primary delivery location at Fort Detrick, MD, with an alternate delivery option to Fort Jackson, SC. All packaging and documentation must be marked with the base contract number SPE2DP-20-D-0002, the delivery order number SPE2DP-26-F-7450, and the unique traceable identifiers W25MWY61940718 and RDD 203, though no specific MIL-STD packaging standards are cited. Invoicing must be submitted electronically through Wide Area WorkFlow in accordance with DFARS 252.232-7003, and payment will be processed by the Defense Finance and Accounting Service at the remit-to address in Columbus, Ohio. The contracting officer is Melissa Rios Thomas, with administrative support provided by John Garbarino; no COTR or COR is explicitly named. The contractor is affirmed as a small business, triggering compliance with FAR 52.212-3 and DFARS 252.212-7001, but no other socioeconomic certifications are claimed. The manufacturer’s CAGE code for the vaccine is 0AZ22, and the product is subject to pharmaceutical quality standards, though no specific regulatory or inspection criteria beyond conformity to contract terms are detailed. The contract is structured as a firm-fixed-price delivery order with zero variance allowance, reflecting a single-line-item procurement under an IDIQ vehicle, with no options, special requirements, or evaluation factors disclosed in the available documentation.